Commonwealth legislation

Therapeutic Goods (Listing) Notice 2015 (No. 3)

RepealedCTH

This Act has been repealed and is no longer in force. It is retained for historical reference.

Jurisdiction

Commonwealth

Collection

legislative instrument

Plain English Summary

1/10 complexity

This notice authorises Polaprezinc (a zinc compound) to be used as an active ingredient in listed (lower‑risk) complementary medicines on the ARTG, limited to oral products and a recommended daily zinc dose of 25 mg or less. It affects supplement manufacturers/importers and consumers by expanding safe formulation options for oral zinc supplements while keeping dose limits to protect safety.

JSON API Health / NDIS / medicines

Deep dive

Want the full deep dive?

Zoe can write the in-depth analysis on top of the summary above: how it works, who it affects and what each part actually does.

Current sections

Direct links to the current provisions in Therapeutic Goods (Listing) Notice 2015 (No. 3).

Therapeutic Goods (Listing) Notice 2015 (No. 3)

meta-content-style-type: text/css meta-content-type: application/xhtml+xml; charset=utf-8 meta-generator: Aspose.Words for .NET 20.2

?xml version="1.0" encoding="utf-8" standalone="no"?>

Therapeutic Goods Act 1989

Therapeutic Goods (Listing) Notice 2015 (No. 3)

I, JOHN SKERRITT, National Manager of the Therapeutic Goods Administration, delegate of the Minister for Health for the purposes of subsection 9A(5) of the Therapeutic Goods Act 1989 (the Act) and acting under that provision, require the following therapeutic goods to be included in the part of the Australian Register of Therapeutic Goods (the Register) for listed goods:

preparations that contain ‘Polaprezinc’ as a therapeutically active ingredient, subject to the following condition:
- the preparation contains a recommended daily dose of 25 milligrams or less of zinc; and
- the preparation is for oral use only.

This Notice commences from the day after it is registered on the Federal Register of Legislative Instruments.

Dated this 25th day of June 2015

(Signed by)

John Skerritt

Delegate of the Minister for Health

Source text

Sourced from the Federal Register of Legislation (legislation.gov.au), CC BY 4.0.

meta-content-style-type: text/css meta-content-type: application/xhtml+xml; charset=utf-8 meta-generator: Aspose.Words for .NET 20.2

?xml version="1.0" encoding="utf-8" standalone="no"?>

Therapeutic Goods Act 1989

Therapeutic Goods (Listing) Notice 2015 (No. 3)

preparations that contain ‘Polaprezinc’ as a therapeutically active ingredient, subject to the following condition:
- the preparation contains a recommended daily dose of 25 milligrams or less of zinc; and
- the preparation is for oral use only.

This Notice commences from the day after it is registered on the Federal Register of Legislative Instruments.

Dated this 25th day of June 2015

(Signed by)

John Skerritt

Delegate of the Minister for Health